Key Development
GE HealthCare has agreed to acquire SOFIE Biosciences for $945 million in cash, adding a U.S. PET radiopharmaceutical manufacturing and distribution network to its Pharmaceutical Diagnostics business. The transaction is expected to close in the first half of 2027, subject to regulatory approvals and other closing conditions.
SOFIE brings 15 CMO sites operating 21 cyclotrons, plus a theranostics-focused CDMO facility. The transaction also gives GE HealthCare U.S. rights to FAPI-74, an F-18 PET tracer currently in Phase III development with potential applications across multiple tumor types. GE HealthCare already held rights to FAPI-74 outside the United States through a 2023 licensing agreement.
GE HealthCare expects SOFIE to grow at a low-double-digit rate and projects the transaction to be accretive to revenue growth, adjusted EBIT margin and adjusted EPS in its first full year of ownership. These remain company projections rather than realized results.
Why It Matters
- In radiopharma, logistics are part of the product. F-18 has a half-life of approximately 110 minutes, making manufacturing proximity, scheduling and delivery reliability directly relevant to patient access.
- GE HealthCare is integrating more of the value chain: cyclotrons, PET imaging, radiotracers, digital workflow and theranostics infrastructure.
- FAPI-74 adds oncology optionality, but remains a Phase III asset rather than an approved pan-cancer imaging standard.
- Radiopharma dealmaking is accelerating. Reuters pointed to Curium’s transaction for Lantheus, worth up to $8 billion, as another sign that strategic value increasingly sits in both pipelines and supply infrastructure.
Healthcare Insight Analysis
Healthcare Insight believes the most valuable asset GE HealthCare may be buying is not FAPI-74.
It is time.
Traditional pharmaceuticals can often be manufactured centrally, warehoused and transported over long distances.
PET radiopharmaceuticals operate under very different economics.
For an F-18 product:
cyclotron → synthesis → quality release → dispatch → hospital → injection → PET imaging
must occur within hours.
That makes geographic manufacturing density a form of distributed infrastructure moat.
A company may own an excellent tracer, but if it cannot manufacture and deliver doses reliably near imaging sites, scientific differentiation may never translate fully into commercial penetration.
SOFIE already manufactures products including FDG, PYLARIFY, FLYRCADO and Neuraceq. The company states that its network delivers more than 675,000 doses annually with 99% cyclotron uptime. These are company-reported metrics, but they illustrate how strongly operational reliability determines value in PET.
The acquisition also pushes GE HealthCare closer to an end-to-end precision imaging platform.
GE already participates in PET/CT scanners, cyclotrons, radiochemistry systems, imaging agents and digital workflows. SOFIE adds the final manufacturing and delivery layer. GE also took full ownership of Nihon Medi-Physics, a major Japanese radiopharmaceutical company, in 2025.
The strategic architecture increasingly looks like:
isotope production → radiochemistry → tracer → distribution → scanner → image interpretation → therapeutic pathway.
That matters as theranostics expands.
Diagnostic imaging is increasingly becoming the gatekeeper for targeted radioligand treatment: identify the molecular target, select the patient, quantify disease, administer treatment and monitor response.
Owning infrastructure across several of those steps could give GE HealthCare greater recurring exposure to each patient journey rather than relying primarily on capital-equipment sales.
But vertical integration creates a commercial tension.
SOFIE is also a contract manufacturer for other radiopharmaceutical providers — some of which may compete with GE HealthCare.
GE has explicitly said SOFIE will continue supplying existing third-party customers and that its own radiopharmaceutical portfolio will continue to use other CMO partners.
That creates an important governance question:
Can SOFIE remain a trusted neutral manufacturing partner when its owner is also a competing radiopharmaceutical company?
Perceived concerns over data, capacity prioritization or supply allocation could weaken part of the strategic value GE is acquiring.
Market Implications
GE HealthCare: can increasingly compete through bundled scanner–tracer–manufacturing–workflow economics rather than individual products.
Radiopharma biotech: manufacturing planning must begin alongside clinical development; approval alone cannot create patient access.
CMOs/CDMOs: cyclotron density, redundancy and delivery reliability are becoming strategic M&A assets.
Hospitals: procurement decisions will increasingly consider supplier proximity, uptime and backup capacity alongside tracer performance.
ANALYTICAL MATRIX
| Dimension | SOFIE Adds | Strategic Value | Risk |
| Final mile | 15 CMO sites / 21 cyclotrons | Patient access | Integration |
| Pipeline | Phase III FAPI-74 | Pan-cancer optionality | Regulatory failure |
| CMO business | Third-party production | Revenue beyond GE portfolio | Channel conflict |
| GE ecosystem | Scanner + tracer + digital | End-to-end platform | Customer concerns |
| Economics | $945m cash deal | Low-double-digit growth expected | Execution / valuation |
The transaction highlights a defining feature of radiopharma economics:
the molecule and the supply chain cannot be valued independently.
If GE HealthCare can preserve SOFIE’s credibility as an industry-wide CMO while using the same network to scale FLYRCADO, FAPI-74 and future agents, the $945 million acquisition may secure something harder to build than another drug pipeline:
a distribution infrastructure where every minute carries economic value.